Structural covariance network topology in individuals at clinical high risk for psychosis: the ENIGMA-CHR Study.

Auditory and visual oddball stimulus processing deficits in clinical high risk for psychosis: Forecasting psychosis risk with N200 and P300.

The impact of COVID-19 pandemic on individuals at clinical high-risk for psychosis: Evidence from eye-tracking measures

ObjectiveAlthough previous studies have reported impaired performance in the reading the mind in the eyes test (RMET), which measures complex emotion recognition abilities, in patients with schizophrenia, reports regarding individuals at clinical high risk (CHR) for psychosis have been inconsistent, mainly due to the interacting confounding effects of general cognitive abilities and age. We compared RMET performances across first-episode psychosis (FEP) patients, CHR individuals, and healthy controls (HCs) while controlling for the effects of both general cognitive abilities and age.MethodsA total of 25 FEP, 41 CHR, and 44 HC subjects matched for age participated in this study. RMET performance scores were compared across the groups using analysis of variance with sex and intelligence quotient as covariates. Exploratory Pearson’s correlation analyses were performed to reveal the potential relationships of RMET scores with clinical symptom severity in the FEP and CHR groups.ResultsRMET performance scores were significantly lower among FEP and CHR participants than among HCs. FEP patients and CHR subjects showed comparable RMET performance scores. RMET scores were negatively correlated with Positive and Negative Syndrome Scale (PANSS) positive symptom subscale scores in the FEP patients. No significant correlation was identified between RMET scores and other clinical scale scores.ConclusionImpaired RMET performance is present from the risk stage of psychosis, which might be related to positive symptom severity in early psychosis. Longitudinal studies are necessary to confirm the stability of complex emotion recognition impairments and their relationship with social functioning in early psychosis patients.

Psychosis rates in autism spectrum disorder (ASD) are 5–35% higher than in the general population. The overlap in sensory and attentional processing abnormalities highlights the possibility of related neurobiological substrates. Previous research has shown that several electroencephalography (EEG)-derived event-related potential (ERP) components that are abnormal in schizophrenia, including P300, are also abnormal in individuals at Clinical High Risk (CHR) for psychosis and predict conversion to psychosis. Yet, it is unclear whether P300 is similarly sensitive to psychosis risk in help-seeking CHR individuals with ASD history. In this exploratory study, we leveraged data from the North American Prodrome Longitudinal Study (NAPLS2) to probe for the first time EEG markers of longitudinal psychosis profiles in ASD. Specifically, we investigated the P300 ERP component and its sensitivity to psychosis conversion across CHR groups with (ASD+) and without (ASD–) comorbid ASD. Baseline EEG data were analyzed from 304 CHR patients (14 ASD+; 290 ASD–) from the NAPLS2 cohort who were followed longitudinally over two years. We examined P300 amplitude to infrequent Target (10%; P3b) and Novel distractor (10%; P3a) stimuli from visual and auditory oddball tasks. Whereas P300 amplitude attenuation is typically characteristic of CHR and predictive of conversion to psychosis in non-ASD sample, in our sample, history of ASD moderated this relationship such that, in CHR/ASD+ individuals, enhanced – rather than attenuated - visual P300 (regardless of stimulus type) was associated with psychosis conversion. This pattern was also seen for auditory P3b amplitude to Target stimuli. Though drawn from a small sample of CHR individuals with ASD, these preliminary results point to a paradoxical effect, wherein those with both CHR and ASD history who go on to develop psychosis have a unique pattern of enhanced neural response during attention orienting to both visual and target stimuli. Such a pattern stands out from the usual finding of P300 amplitude reductions predicting psychosis in non-ASD CHR populations and warrants follow up in larger scale, targeted, longitudinal studies of those with ASD at clinical high risk for psychosis.

BackgroundDisrupted white matter (WM) microstructure has been commonly identified in youth at clinical high risk (CHR) for psychosis. Several lines of evidence suggest that fatty acids, especially unsaturated fatty acids...

Recent studies show that accelerated cortical gray matter (GM) volume reduction seen in anatomical MRI can help distinguish between individuals at clinical high risk (CHR) for psychosis who will develop psychosis and those who will not. This reduction is thought to result from an accumulation of microstructural changes, such as decreased spine density and dendritic arborization. Detecting the microstructural sources of these changes before they accumulate is crucial, as volume reduction likely indicates an underlying neurodegenerative process. Our study aimed to detect these microstructural GM alterations using diffusion MRI (dMRI).We tested for baseline and longitudinal group differences in anatomical and dMRI data from 160 individuals at CHR and 96 healthy controls (HC) acquired in a single imaging site. Eight cortical lobes were examined for GM volume and GM microstructure. A novel dMRI measure, interstitial free water (iFW), was used to quantify GM microstructure by eliminating cerebrospinal fluid contribution. Additionally, we assessed whether these measures differentiated the 33 individuals at CHR who developed psychosis (CHR-P) from the 127 individuals at CHR who did not (CHR-NP).At baseline the CHR group had significantly higher iFW than HC in the prefrontal, temporal, parietal, and occipital lobes, while volume was reduced only in the temporal lobe. Neither iFW nor volume differentiated between the CHR-P and CHR-NP groups at baseline. However, in most brain areas, the CHR-P group demonstrated significantly accelerated iFW increase and volume reduction with time than the CHR-NP group.Our results demonstrate that microstructural GM changes in individuals at CHR have a wider extent than volumetric changes and they predate the acceleration of brain changes that occur around psychosis onset. Microstructural GM changes are thus an early pathology at the prodromal stage of psychosis that may be useful for early detection and a better mechanistic understanding of psychosis development.

The development of adverse clinical outcomes in patients with psychosis has been associated with behavioral and neuroanatomical deficits related to emotion processing. However, the association between alterations in brain regions subserving emotion processing and clinical outcomes remains unclear. To examine the association between alterations in emotion processing and regional gray matter volumes in individuals at clinical high risk (CHR) for psychosis, and the association with subsequent clinical outcomes. This naturalistic case-control study with clinical follow-up at 12 months was conducted from July 1, 2010, to August 31, 2016, and collected data from 9 psychosis early detection centers (Amsterdam, Basel, Cologne, Copenhagen, London, Melbourne, Paris, The Hague, and Vienna). Participants (213 individuals at CHR and 52 healthy controls) were enrolled in the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) project. Data were analyzed from October 1, 2018, to April 24, 2019. Emotion recognition was assessed with the Degraded Facial Affect Recognition Task. Three-Tesla magnetic resonance imaging scans were acquired from all participants, and gray matter volume was measured in regions of interest (medial prefrontal cortex, amygdala, hippocampus, and insula). Clinical outcomes at 12 months were evaluated for transition to psychosis using the Comprehensive Assessment of At-Risk Mental States criteria, and the level of overall functioning was measured through the Global Assessment of Functioning [GAF] scale. A total of 213 individuals at CHR (105 women [49.3%]; mean [SD] age, 22.9 [4.7] years) and 52 healthy controls (25 women [48.1%]; mean [SD] age, 23.3 [4.0] years) were included in the study at baseline. At the follow-up within 2 years of baseline, 44 individuals at CHR (20.7%) had developed psychosis and 169 (79.3%) had not. Of the individuals at CHR reinterviewed with the GAF, 39 (30.0%) showed good overall functioning (GAF score, ≥65), whereas 91 (70.0%) had poor overall functioning (GAF score, <65). Within the CHR sample, better anger recognition at baseline was associated with worse functional outcome (odds ratio [OR], 0.88; 95% CI, 0.78-0.99; P = .03). In individuals at CHR with a good functional outcome, positive associations were found between anger recognition and hippocampal volume (ze = 3.91; familywise error [FWE] P = .02) and between fear recognition and medial prefrontal cortex volume (z = 3.60; FWE P = .02), compared with participants with a poor outcome. The onset of psychosis was not associated with baseline emotion recognition performance (neutral OR, 0.93; 95% CI, 0.79-1.09; P = .37; happy OR, 1.03; 95% CI, 0.84-1.25; P = .81; fear OR, 0.98; 95% CI, 0.85-1.13; P = .77; anger OR, 1.00; 95% CI, 0.89-1.12; P = .96). No difference was observed in the association between performance and regional gray matter volumes in individuals at CHR who developed or did not develop psychosis (FWE P < .05). In this study, poor functional outcome in individuals at CHR was found to be associated with baseline abnormalities in recognizing negative emotion. This finding has potential implications for the stratification of individuals at CHR and suggests that interventions that target socioemotional processing may improve functional outcomes.

Antipsychotics (APs) are often used among individuals with clinical high risk (CHR) for psychosis and affect cortical thickness (CT). Whether clinical and CT changes after initial AP use correlate with long-term clinical outcomes remains largely unknown. One hundred and thirty-eight CHRs and 65 healthy controls accepted 2 MRI scans at an interval of 2months. CHRs were categorized as responders (n= 53) and non-responders (n= 69) based on their response to APs after 2-month treatment. According to 2-year outcomes, they were also subdivided into converters (n= 26) and non-converters (n= 96). The relationships among short-term CT changes, AP effects, and long-term outcomes were explored. At baseline, CHRs had CT reduction in the right inferior temporal cortex with a correlation with clinical symptoms. At 2month, CHRs showed steeper gray matter loss in bilateral frontotemporal regions than healthy controls. Cortical thickness change rates of the clusters located in bilateral middle temporal and right lateral orbitofrontal cortex were negatively correlated with the cumulative AP dose. Furthermore, 2-year psychosis conversion rate was significantly higher in non-responders than responders (33.3% vs 5.1%). A random forest model based on demographic, clinical, baseline, and longitudinal CT variables predicted 2-year conversion with an AUC of 0.90 (accuracy: 0.83, sensitivity: 0.78, and specificity: 0.89), with model predictive power driven primarily by symptom and CT variables. These findings contribute valuable insights into the potential impact of early AP treatment on brain morphology and clinical trajectories and highlight the importance of monitoring the initial treatment responses.

Thalamocortical dysrhythmia (TCD) is a model characterized by abnormal resting-state thalamic oscillatory patterns where the alpha rhythm is replaced by cross-frequency coupling of low- and high-frequency rhythms. Although disrupted thalamic function is a suggested important pathophysiological mechanism underlying schizophrenia, knowledge regarding the TCD model in schizophrenia spectrum disorder (SSD) patients and individuals at clinical high risk (CHR) for psychosis is limited. A total of 169 SSD patients, 106 individuals at CHR for psychosis, and 105 healthy controls (HCs) underwent resting-state electroencephalography recordings. We performed mean global field power (MGFP) spectral analysis between 1 and 49 Hz as well as source-level theta phase-gamma amplitude coupling (TGC) analysis and compared resting-state oscillatory patterns across groups. Correlations between altered TGC values and psychotic symptom severity in the patient group were investigated. Spectral MGFP of low- and high-frequencies was larger in the SSD and CHR groups than in the HC group. The TGC of SSD patients was greater than that of HCs in the right frontal, right parietal, and left and right limbic lobes. Greater TGC in the right frontal and limbic lobes was associated with positive symptom severity in SSD patients. However, TGC in the CHR group was comparable to that in the HCs and was smaller than that in the SSD group in widespread cortical regions. The TCD pattern may be apparent after frank psychotic disorder onset in tandem with overt positive symptoms. A psychosis-risk state without overt psychotic symptoms could be characterized by abnormally increased low- and high-frequency activities with relatively preserved TGC.

ABSTRACTIntroductionThe aim of our study was to assess the performance of the Prodromal Questionnaire‐16 (PQ‐16) and the Perceptual and Cognitive Aberrations scale (PCA) to screen for clinical high risk for psychosis (CHR) in a sample of nonhelp‐seeking subjects from São Paulo, Brazil.MethodsIndividuals aged 18–35 years were interviewed with the PQ‐16 and the PCA. Those with a combined score > 10 on the PQ‐16 + PCA were called for assessment with the Structured Interview for Psychosis‐Risk Syndromes (SIPS). Seventy‐five individuals were deemed as CHR and 99 as healthy comparison; 44 randomly selected individuals (PQ‐16 + PCA scores < 10) joined as further controls. All participants had no DSM‐5 diagnosis. Scores of the PCA, PQ‐16 (total score and distress index), and their combinations were analysed.ResultsAll the proposed scorings significantly distinguished between CHR and control subjects. Considering a 7% CHR prevalence in the population, PQ‐16 score mathematically showed the best performance (AUC = 0.713), followed by the PQ‐16 score + PCA (AUC = 0.701). PQ‐16 distress had the worst performance (AUC = 0.642).ConclusionsData provides further evidence for the use of the PQ‐16 score as an effective instrument to search for CHR states through active screening in the community. Future research should address its potential in helping CHR identification and thus reducing delays in care and minimising the risk of false positives.

Patterns of premorbid functioning in individuals at clinical high risk of psychosis

Striatal cerebral blood flow, executive functioning, and fronto-striatal functional connectivity in clinical high risk for psychosis

Metacognition has been described as the knowledge of our own cognitive processes. Metacognitive deficits are common in schizophrenia, but little is known about metacognition before the onset of full-blown psychosis. This study aimed to longitudinally characterize metacognition in a sample of individuals at clinical high risk (CHR) for psychosis, and to determine if metacognition was related to later conversion to psychosis. Participants (153 CHR individuals; 68 help seeking controls, HSC) were part of the large multi-site PREDICT study, which sought to determine predictors of conversion to psychosis. They were tested at baseline and 6 months using the Meta-Cognitions Questionnaire (MCQ) that has five sub-scales assessing different domains of metacognition. RESULTS of the mixed-effect models demonstrated significantly poorer scores at baseline for the CHR group compared to the HSC group in Negative beliefs about uncontrollability, Negative beliefs and the overall MCQ score. At the 6-month assessment, no difference was observed in metacognition between the two groups, but both groups showed improvement in metacognition over time. Those who later converted to psychosis had poorer performance on metacognitive beliefs at baseline. A poorer performance in metacognition can be seen as a marker of developing a full blown psychotic illness and confirms the potential value of assessing metacognitive beliefs in individuals vulnerable for psychosis.

Hallucinations are considered one of the primary symptoms of psychosis; however, their neural basis remains unclear. Voxel-based morphometry (VBM)1 studies have associated hallucinations with gray matter (GM) volume reduction in the superior temporal gyrus in schizophrenia.2 Although hallucinations are associated with brain connectivity,3 few studies have investigated their relationship with white matter (WM) volume. Moreover, these studies have shown inconsistent results.4, 5 The chronicity of illness and long-term medications for schizophrenia may limit the interpretation of previous findings.2 Thus, hallucination studies in clinical high risk for psychosis (CHR) and first-episode psychosis (FEP) are required, with minimal effects of chronicity of illness and medication. However, no VBM study has examined the relationship between hallucinations and WM volume in CHR and FEP. Therefore, we aimed to investigate the regional GM and WM volumes associated with hallucinations in CHR and FEP. We enrolled 57 individuals with CHR, 50 individuals with FEP, and 33 healthy controls (HCs). The Comprehensive Assessment of At-Risk Mental States-Japanese version6 was used to confirm whether ultra-high risk criteria7 were met. Table S1 summarizes the demographic and clinical data of the patients. Hallucination severity was assessed using the Positive and Negative Syndrome Scale (PANSS)8 P3 score. Fig. S1 shows the distribution of the severity of hallucinations. Some of those with a PANSS P3 score of 3 or higher were classified as having CHR because of the low frequency and duration of hallucinations. Magnetic resonance imaging (MRI) data were acquired with a 1.5-T Philips scanner. We examined the association of GM and WM volume with hallucination severity in the group that combined patients with CHR and FEP (CHR/FEP combined group) and performed group comparisons of GM and WM volume between the CHR/FEP combined and HC groups. Age, sex, and intracranial volume were entered as nuisance covariates for each analysis. VBM analysis was conducted using DARTEL9 in SPM12 (https://www.fil.ion.ucl.ac.uk/spm/software/spm12/) with standard smoothing of 8-mm full width at half maximum (FWHM). The initial statistical threshold was set at P < 0.001, uncorrected at the voxel level. The extent threshold for cluster size was set based on the expected number of voxels per cluster provided by SPM. Familywise error (FWE) correction at the cluster level (P < 0.05) was applied to identify significant clusters. Appendix S1 provides detailed information on these methods. This study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Tohoku University Graduate School of Medicine and Tohoku University Hospital. Written informed consent was obtained from participants aged 18 years or older and from the parents of those under 18 years of age, with written assent from the participants. The anonymity of participants was preserved. WM volume was not significantly correlated with hallucination severity in the CHR/FEP combined group after FWE correction at the cluster level. Reanalysis with 15-mm or 20-mm FWHM filtering did not show significant associations. Additionally, there was no significant difference in the GM and WM volumes between the CHR/FEP combined and HC groups. No regional GM volume abnormalities were significantly correlated with hallucination severity in the CHR/FEP combined group. Appendix S1, Figs. S2–S5, and Tables S2–S5 provide uncorrected results and detailed information regarding these results. To the best of our knowledge, this is the first VBM study to investigate WM volume related to hallucinations in CHR and FEP. We found no significant correlation between WM volume and hallucination severity. In contrast to previous studies in schizophrenia,2, 4, 5 this study examined the brain volume association of hallucinations in CHR and FEP. CHR and FEP are heterogeneous groups in the early stages of mental illness and do not necessarily convert to schizophrenia. Our results indicate that brain disturbances involved in hallucinations in CHR and FEP may be more subtle and/or inconsistent with those in schizophrenia. Diffusion tensor imaging, a neuroimaging method applied to CHR,10 may be suitable for examining structural abnormalities in the development of hallucinations. This study has some limitations. First, information regarding hallucinations is not detailed. Second, the cross-sectional design limited the interpretation of our findings. Third, we used an MRI scanner with a lower field strength than that of recent studies.4 Fourth, there were significant age differences between the groups. Fifth, automatic quality assurance for MRI scans was not performed. In conclusion, advanced neuroimaging studies are needed to reveal the mechanism of hallucinations. This work was supported by JSPS KAKENHI (grant number 18K07586). We thank the participants, staff of the SAFE clinic, and radiological technologists. The authors declare no conflicts of interest. Appendix S1. Supporting information Figure S1. Distribution of hallucination severity. CHR, clinical high risk for psychosis; FEP, first-episode psychosis; PANSS, Positive and Negative Syndrome Scale. Figure S2. Brain regions with lower gray matter volume in the CHR/FEP group compared to the HC group. Statistical threshold was set at P < 0.001, uncorrected at the voxel level. The threshold extent for cluster size was set to k = 117 based on the expected number of voxels per cluster provided by SPM. The full width at half maximum was set to 8-mm. CHR, clinical high risk for psychosis; FEP, first-episode psychosis; HC, healthy controls; SPM, Statistical Parametric Mapping Figure S3. Brain regions with lower white matter volume in the CHR/FEP group compared to the HC group. Statistical threshold was set at P < 0.001, uncorrected at the voxel level. The threshold extent for cluster size was set to k = 129 based on the expected number of voxels per cluster provided by SPM. The full width at half maximum was set to 8-mm. CHR, clinical high risk for psychosis; FEP, first-episode psychosis; HC, healthy controls; SPM, Statistical Parametric Mapping Figure S4. Positive correlation between gray matter volume and hallucination severity in the patients at clinical high risk for psychosis. Statistical threshold was set at P < 0.001, uncorrected at the voxel level. The threshold extent for cluster size was set to k = 101 based on the expected number of voxels per cluster provided by the SPM. The full width at half maximum was set to 8-mm. SPM, Statistical Parametric Mapping Figure S5. Negative correlation between white matter volume and hallucination severity in the patients at clinical high risk for psychosis. Statistical threshold was set at P < 0.001, uncorrected at the voxel level. The threshold extent for cluster size was set to k = 121 based on the expected number of voxels per cluster provided by the SPM. The full width at half maximum was set to 8-mm. SPM, Statistical Parametric Mapping Table S1. Demographic and clinical characteristics of the participants. †Educational level, CP-equivalent dose on MRI scan, PANSS positive, PANSS negative, PANSS general, PANSS total, PANSS P3: hallucinatory behavior, and days from enrollment to MRI scan were analyzed using the t-test. Age and intracranial volume were analyzed using one-way analysis of variance. Sex and antipsychotic use were analyzed using the chi-squared test. Significant results are shown in bold. CHR, clinical high risk for psychosis; CP-equivalent, chlorpromazine equivalent; FEP, first-episode psychosis; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale. Table S2. Between-group comparison of regional gray matter volume. CHR/FEP < HC (extent threshold: 117 voxels). † Uncorrected p-value at voxel level. ‡ familywise error-corrected p-value at the cluster level. k, cluster size at P < 0.001 (uncorrected); CHR, clinical high risk for psychosis; FEP, first-episode psychosis; HC, healthy controls; L/R, left/right hemisphere; MNI, Montreal Neurological Institute. The extent threshold for cluster size was set based on the expected number of voxels per cluster provided by the SPM. The full width at half maximum was set to 8-mm. Table S3. Between group comparison of regional white matter volume. CHR/FEP < HC (extent threshold: 129 voxels). † Uncorrected P-value at voxel level. ‡ familywise error-corrected p-value at the cluster level. k, cluster size at P < 0.001 (uncorrected); CHR, clinical high risk for psychosis; FEP, first-episode psychosis; HC, healthy controls; L/R, left/right hemisphere; MNI, Montreal Neurological Institute. The extent threshold for cluster size was set based on the expected number of voxels per cluster provided by the SPM. The full width at half maximum was set to 8-mm. Table S4. Correlation between gray matter volume and hallucination severity in the patients with CHR. Positive correlation (extent threshold: 101 voxels). † Uncorrected p-value at voxel level. ‡ familywise error-corrected p-value at the cluster level. k, cluster size at P < 0.001 (uncorrected); CHR, clinical high risk for psychosis; L/R, left/right hemisphere; MNI, Montreal Neurological Institute. The extent threshold for cluster size was set based on the expected number of voxels per cluster provided by the SPM. The full width at half maximum was set to 8-mm. Table S5. Correlation between white matter volume and hallucination severity in the patients with CHR. Negative correlation (extent threshold: 121 voxels). † Uncorrected p-value at voxel level. ‡ familywise error-corrected p-value at the cluster level. k, cluster size at P < 0.001 (uncorrected); CHR, clinical high risk for psychosis; L/R, left/right hemisphere; MNI, Montreal Neurological Institute. The extent threshold for cluster size was set based on the expected number of voxels per cluster provided by the SPM. The full width at half maximum was set to 8-mm. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

The developmental course of daily functioning prior to first psychosis-onset remains poorly understood. This study explored age-related periods of change in social and role functioning. The longitudinal study included youth (aged 12-23, mean follow-up years = 1.19) at clinical high risk (CHR) for psychosis (converters [CHR-C], n = 83; nonconverters [CHR-NC], n = 275) and a healthy control group (n = 164). Mixed-model analyses were performed to determine age-related differences in social and role functioning. We limited our analyses to functioning before psychosis conversion; thus, data of CHR-C participants gathered after psychosis onset were excluded. In controls, social and role functioning improved over time. From at least age 12, functioning in CHR was poorer than in controls, and this lag persisted over time. Between ages 15 and 18, social functioning in CHR-C stagnated and diverged from that of CHR-NC, who continued to improve (p = .001). Subsequently, CHR-C lagged behind in improvement between ages 21 and 23, further distinguishing them from CHR-NC (p < .001). A similar period of stagnation was apparent for role functioning, but to a lesser extent (p = .007). The results remained consistent when we accounted for the time to conversion. Our findings suggest that CHR-C start lagging behind CHR-NC in social and role functioning in adolescence, followed by a period of further stagnation in adulthood.